Advertisement
Mayo Clinic Proceedings Home

Primary Myelodysplastic Syndromes

The Mayo Clinic Experience With 1000 Patients
Published:November 03, 2015DOI:https://doi.org/10.1016/j.mayocp.2015.08.022

      Abstract

      Objectives

      To share our 25 years of experience with patients with primary myelodysplastic syndromes (MDS) and to describe the natural history of the disease including presenting clinical and laboratory characteristics and long-term disease outcomes.

      Patients and Methods

      One thousand consecutive patients with primary MDS evaluated at Mayo Clinic between January 1, 1989, and May 1, 2014, were considered. The Revised International Prognostic Scoring System and other risk models were applied for risk stratification. Separate analyses were conducted for patients diagnosed before 2005 (n=531) and after 2005 (n=469).

      Results

      Eighty-five percent of patients were older than 60 years (median age, 72 years), with 69% being men. The median follow-up period was 27 months (range, 0-300 months), during which time 808 (81%) deaths and 129 (13%) leukemic transformations were documented. Median survival and leukemic transformation rates were similar in patients diagnosed before or after 2005, despite the significantly higher use of hypomethylating agents in the latter group: 33 months vs 28 months (P=.46) and 13% vs 10% (P=.92), respectively. Revised International Prognostic Scoring System risk distribution was similar in patients diagnosed before or after 2005 (P=.23): 17% were categorized as very low, 36% low, 21% intermediate, 15% high, and 11% very high risk, with a median survival of 72, 43, 24, 18, and 7 months, respectively (P<.001). We found Revised International Prognostic Scoring System cytogenetic risk categorization to be suboptimal in its performance, whereas contemporary prognostic models were broadly similar in their performance.

      Conclusion

      The poor outcome in patients with MDS does not appear to have improved over time. Current risk stratification systems for MDS are not substantially different from each other. There is a dire need for drugs that are truly disease modifying and risk models that incorporate prognostically relevant mutations.

      Abbreviations and Acronyms:

      HR (hazard ratio), IPSS (International Prognostic Scoring System), IPSS-R (Revised International Prognostic Scoring System), FAB (French American British), LT (leukemic transformation), MDAS (MD Anderson score), MDS (myelodysplastic syndrome), MK (monosomal karyotype), RAEB-1 (refractory anemia with excess blasts-1), RCMD (refractory cytopenia with multilineage dysplasia), WHO (World Health Organization), WPSS (World Health Organization Prognostic Scoring System)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Vardiman J.W.
        • Thiele J.
        • Arber D.A.
        • et al.
        The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
        Blood. 2009; 114: 937-951
        • Tefferi A.
        • Vardiman J.W.
        Myelodysplastic syndromes.
        N Engl J Med. 2009; 361: 1872-1885
        • Boudard D.
        • Sordet O.
        • Vasselon C.
        • et al.
        Expression and activity of caspases 1 and 3 in myelodysplastic syndromes.
        Leukemia. 2000; 14: 2045-2051
        • Ebert B.L.
        • Pretz J.
        • Bosco J.
        • et al.
        Identification of RPS14 as a 5q- syndrome gene by RNA interference screen.
        Nature. 2008; 451: 335-339
        • Schneider R.K.
        • Ademà V.
        • Heckl D.
        • et al.
        Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.
        Cancer Cell. 2014; 26: 509-520
        • Paquette R.L.
        • Landaw E.M.
        • Pierre R.V.
        • et al.
        N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome.
        Blood. 1993; 82: 590-599
        • Harada H.
        • Harada Y.
        • Niimi H.
        • Kyo T.
        • Kimura A.
        • Inaba T.
        High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.
        Blood. 2004; 103: 2316-2324
        • Boultwood J.
        • Perry J.
        • Pellagatti A.
        • et al.
        Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia.
        Leukemia. 2010; 24: 1062-1065
        • Walter M.J.
        • Ding L.
        • Shen D.
        • et al.
        Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.
        Leukemia. 2011; 25: 1153-1158
        • Langemeijer S.M.
        • Kuiper R.P.
        • Berends M.
        • et al.
        Acquired mutations in TET2 are common in myelodysplastic syndromes.
        Nat Genet. 2009; 41: 838-842
        • Nikoloski G.
        • Langemeijer S.M.
        • Kuiper R.P.
        • et al.
        Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.
        Nat Genet. 2010; 42: 665-667
        • Patnaik M.M.
        • Hanson C.A.
        • Hodnefield J.M.
        • et al.
        Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.
        Leukemia. 2012; 26: 101-105
        • Yoshida K.
        • Sanada M.
        • Shiraishi Y.
        • et al.
        Frequent pathway mutations of splicing machinery in myelodysplasia.
        Nature. 2011; 478: 64-69
        • Harutyunyan A.
        • Klampfl T.
        • Cazzola M.
        • Kralovics R.
        p53 lesions in leukemic transformation.
        N Engl J Med. 2011; 364: 488-490
        • Patnaik M.M.
        • Lasho T.L.
        • Hodnefield J.M.
        • et al.
        SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.
        Blood. 2012; 119: 569-572
        • Vannucchi A.M.
        • Lasho T.L.
        • Guglielmelli P.
        • et al.
        Mutations and prognosis in primary myelofibrosis.
        Leukemia. 2013; 27: 1861-1869
        • Chang C.
        • Storer B.E.
        • Scott B.L.
        • et al.
        Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders.
        Blood. 2007; 110: 1379-1387
        • Greenberg P.
        • Cox C.
        • LeBeau M.M.
        • et al.
        International scoring system for evaluating prognosis in myelodysplastic syndromes.
        Blood. 1997; 89 ([published corrections appear in Blood. 1998;91(3):1100]): 2079-2088
        • Malcovati L.
        • Germing U.
        • Kuendgen A.
        • et al.
        Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.
        J Clin Oncol. 2007; 25: 3503-3510
        • Kantarjian H.
        • O'Brien S.
        • Ravandi F.
        • et al.
        Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
        Cancer. 2008; 113: 1351-1361
        • Greenberg P.L.
        • Tuechler H.
        • Schanz J.
        • et al.
        Revised International Prognostic Scoring System for myelodysplastic syndromes.
        Blood. 2012; 120: 2454-2465
        • Bejar R.
        • Stevenson K.
        • Abdel-Wahab O.
        • et al.
        Clinical effect of point mutations in myelodysplastic syndromes.
        N Engl J Med. 2011; 364: 2496-2506
        • Bejar R.
        • Stevenson K.E.
        • Caughey B.A.
        • et al.
        Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.
        J Clin Oncol. 2012; 30: 3376-3382
      1. Shaffer L.G. Slovak M.L. Campbell L.J. ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009). Karger, Basel2009
        • Silverman L.R.
        • McKenzie D.R.
        • Peterson B.L.
        • et al.
        Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
        J Clin Oncol. 2006; 24: 3895-3903
        • Fenaux P.
        • Mufti G.J.
        • Hellstrom-Lindberg E.
        • et al.
        International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
        Lancet Oncol. 2009; 10: 223-232
        • List A.
        • Kurtin S.
        • Roe D.J.
        • et al.
        Efficacy of lenalidomide in myelodysplastic syndromes.
        N Engl J Med. 2005; 352: 549-557
        • List A.
        • Dewald G.
        • Bennett J.
        • et al.
        Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
        N Engl J Med. 2006; 355: 1456-1465
        • Kuendgen A.
        • Strupp C.
        • Aivado M.
        • et al.
        Myelodysplastic syndromes in patients younger than age 50.
        J Clin Oncol. 2006; 24: 5358-5365
        • Germing U.
        • Strupp C.
        • Kündgen A.
        • et al.
        No increase in age-specific incidence of myelodysplastic syndromes.
        Haematologica. 2004; 89: 905-910
        • Schanz J.
        • Tüchler H.
        • Solé F.
        • et al.
        New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.
        J Clin Oncol. 2012; 30: 820-829
        • Gangat N.
        • Patnaik M.M.
        • Begna K.
        • et al.
        Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes.
        Am J Hematol. 2013; 88: 690-693
        • Patnaik M.M.
        • Hanson C.A.
        • Hodnefield J.M.
        • Knudson R.
        • Van Dyke D.L.
        • Tefferi A.
        Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype.
        Leukemia. 2011; 25: 266-270
        • van Gelder M.
        • de Wreede L.C.
        • Schetelig J.
        • et al.
        Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia.
        Leukemia. 2013; 27: 879-888
        • Neukirchen J.
        • Nachtkamp K.
        • Schemenau J.
        • et al.
        Change of prognosis of patients with myelodysplastic syndromes during the last 30 years.
        Leuk Res. 2015; 39: 679-683